Comparison of droplet digital PCR and conventional quantitative PCR for measuring EGFR gene mutation

Experimental and Therapeutic Medicine

Volumn 9, Issue 4, 2015, Pages 1383-1388

  Zhang, Bo ^a   Xu, Chun Wei ^a   Shao, Yun ^a   Wang, Huai Tao ^a   Wu, Yong Fang ^a   Song, Ye Ying ^a   Li, Xiao Bing ^a   Zhang, Zhe ^b   Wang, Wen Jing ^b   Li, Li Qiong ^b   Cai, Cong Li ^b  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b Leador Co Ltd   (China)

Author keywords

Droplet digital polymerase chain reaction; Epidermal growth factor receptor gene mutation; Non small cell lung cancer; Quantitative polymerase chain reaction

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GENOMIC DNA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CONVENTIONAL QUANTITATIVE POLYMERASE CHAIN REACTION; DROPLET DIGITAL POLYMERASE CHAIN REACTION; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MIDDLE AGED; NON SMALL CELL LUNG CANCER; POLYMERASE CHAIN REACTION;

EID: 84923016836     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2015.2221     Document Type: Article

References (22)

1. Bai H, Mao L, Wang HS, et al: Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non small cell lung cancer. J Clin Oncol 27: 2653-2659, 2009.
2. Franklin WA, Veve R, Hirsch FR, Helfrich BA and Bunn PA Jr: Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol 29 (1 Suppl 4): 3-14, 2002.
3. Wang J, Ramakrishnan R, Tang Z, et al: Quantifying EGFR alterations in the lung cancer genome with nanofluidic digital PCR arrays. Clin Chem 56: 623-632, 2010.
4. Sharma SV, Bell DW, Settleman J and Haber DA: Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7: 169-181, 2007.
5. Fukuoka M, Yano S, Giaccone G, et al: Multi institutional randomized phase II trial of gefitinib for previously treated patients with advanced non small cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21: 2237-2246, 2003.
6. Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non small cell lung cancer: a randomized trial. JAMA 290: 2149-2158, 2003.
7. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non small cell lung cancer. N Engl J Med 353: 123-132, 2005.
8. Yamada T, Azuma K, Muta E, et al: EGFR T790M mutation as a possible target for immunotherapy; identification of HLA A*0201 restricted T cell epitopes derived from the EGFR T790M mutation. PLoS One 8: e78389, 2013.
9. Hirsch FR, Varella Garcia M, Bunn PA Jr, et al: Molecular predictors of outcome with gefitinib in a phase III placebo controlled study in advanced non small cell lung cancer. J Clin Oncol 24: 5034-5042, 2006.
10. Pao W and Ladanyi M: Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res 13: 4954-4955, 2007.
11. Kimura H, Kasahara K, Kawaishi M, et al: Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non small cell lung cancer. Clin Cancer Res 12: 3915-3921, 2006.
12. Whale AS, Huggett JF, Cowen S, et al: Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation. Nucleic Acids Res 40: e82, 2012.
13. Yung TK, Chan KC, Mok TS, Tong J, To KF and Lo YM: Single molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non small cell lung cancer patients. Clin Cancer Res 15: 2076-2084, 2009.
14. Nagai Y, Miyazawa H, Huqun, et al: Genetic heterogeneity of the epidermal growth factor receptor in non small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid locked nucleic acid PCR clamp. Cancer Res 65: 7276-7282, 2005.
15. Thomas RK, Nickerson E, Simons JF, et al: Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med 12: 852-855, 2006.
16. Zhou Q, Zhang XC, Chen ZH, et al: Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non small cell lung cancer. J Clin Oncol 29: 3316-3321, 2011.
17. Shigaki H, Baba Y, Watanabe M, et al: PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma. Clin Cancer Res 19: 2451-2459, 2013.
18. Janjigian YY, Tang LH, Coit DG, et al: MET expression and amplification in patients with localized gastric cancer. Cancer Epidemiol Biomarkers Prev 20: 1021-1027, 2011.
19. Azuara D, Ginesta MM, Gausachs M, et al: Nanofluidic digital PCR for KRAS mutation detection and quantification in gastrointestinal cancer. Clin Chem 58: 1332-1341, 2012.
20. Gutiérrez C, Rodriguez J, Patiño García A, García Foncillas J, and Salgado J: KRAS mutational status analysis of peripheral blood isolated circulating tumor cells in metastatic colorectal patients. Oncol Lett 6: 1343-1345, 2013.
21. Marchetti A, Del Grammastro M, Felicioni L, et al: Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: Toward a real time liquid biopsy for treatment. PLoS One 9: e103883, 2014.
22. Mostert B, Jiang Y, Sieuwerts AM, et al: KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. Int J Cancer 133: 130-141, 2013.